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ABSTRACT. Background: Major depressive disorder (MDD) commonly takes a 
relapsing form. Transcranial magnetic stimulation (TMS) has be suggested as a 
means of maintaining remission. Brief courses of TMS at about monthly intervals 
appear to provide health benefits. Objective: To examine whether such brief courses 
of TMS are better conceptualized as maintaining remission, or as the provision of 
early relapse treatment. Method: 25 series of treatment (18 different patients) were 
considered. Pre- and post-treatment 6-item Hamilton Depression Rating Scale 
(HAMD6) and 7 visual analogue scales (VASs) were collected, along with pre-
treatment Clinical Global Impression-Severity (CGI-S) and post-treatment CGI-
Improvement (I). Results: Pre-treatment HAMD6 and CGI-S indicated that many 
patients were symptomatic and in early relapse. Post-treatment HAMD6 indicated 
that many patients had achieved remission, and this was supported by the CGI-I. The 
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VAS scores also improved. Conclusions: Short courses of TMS at about monthly 
intervals have beneficial results and are better conceptualized as early relapse 
treatment (ERT). 
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Introduction  
 
Major depressive disorder (MDD) is painful and disabling. Remission is dif- 
ficult to achieve (Trivedi et al., 2006), and relapse commonly occurs (Berwain 
et al., 2016). Should the remitted state feature any residual symptoms, 
relapse is even more likely (Paykel et al., 1995). 
Transcranial magnetic stimulation (TMS) has proven to be effective in 
acute treatment of drug resistant MDD (Fitzgerald et al., 2016), but as with 
remissions induced by other treatments, relapse is common in the following 
months (Dannon et al., 2002). One study found that following TMS-induced 
remission, relapse occurred at approximately 5 months, and importantly, that 
the reintroduction of TMS often effected a further remission (Demirtas-
Tatlidede et al., 2008). 
There is interest in TMS not only as a treatment of acute MDD, but also, 
as a means of keeping people well, once remission has been achieved. This 
particularly applies to those patients with well-established MDD and a his- 
tory of frequent relapse. The term “maintenance” (M-)TMS has frequently 
been employed – reflecting the hope that occasional TMS may be effective 
in maintaining hard-won remissions. The term continuing (C-)TMS has been 
used interchangeably with M-TMS and there is a need for terminological 
agreement (Levkovitz et al., 2015). A popular protocol, has been, once 
remission has been achieved, to continue providing stimulation sessions, but 
less frequently, such as twice per week (Perera et al., 2016) and once per 
month (Philip et al., 2016).  
Clustered maintenance (CM-)TMS is the term applied to clusters of 5 
TMS sessions delivered over 2 days, at monthly intervals (Fitzgerald et al., 
2013). The authors found this form of care successfully reduced the frequency 
of relapses (or in other words, kept patients well for longer). In conversation 
with our group, the devisor of CM-TMS (Prof Paul Fitzgerald, Monash 
University) advised that the 5 sessions could also be delivered over 3 or 5 
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days. We adopted this model of care, hoping to reduce the suffering and 
costs of chronic MDD. (Stimulation parameters: 120% MT, 10Hz, 4s trains, 
75 trains.)  
In an in-press poster (Rybak et al., 2017) we offered an account of our 
experience with 16 patients treated with CM-TMS in a non-academic 
inpatient setting. In the early stages of this service, the period between series 
is set at 4 weeks, but this varied according to clinical response and patient 
preference. Recently, the average period between series was 5.8 weeks (Rybak 
et al., 2017). These patients had remained relatively well for an average of 
21.7 months. In a cross-sectional prospective assessment, we found their 
average Clinical Global Impression – Severity (CGI-S) indicated a point 
between borderline and mildly ill. Following treatment, visual analogue scale 
(VAS) responses for depression and sleep problems both improved, and the 
CGI-Improvement indicated a point between minimally and much improved. 
These results raised the possibility that CM-TMS, in our hands, at least, 
was not maintaining remission, but rather, providing early remission treat- 
ment [ERT]. The current paper describes an investigation as to whether our 
service would be better described as providing ERT-TMS.  
 
Method  
 
Ethical approval for this study was not required as we used only data col- 
lected in routine clinical practice and the identity of no patient was revealed.  
In accordance with the latest standards (Perera et al., 2016) we recently 
upgraded our outcome assessment methods. Before and after series of treat- 
ments, clinicians administer the six-item Hamilton Depression Rating Scale 
(HAMD6) (O’Sullivan et al., 1997) in the structured/scripted form (Williams, 
1988). Totals were calculated. Five (5) or more was taken as indicating 
relapse (Kyle et al., 2016).   
Before and after each series we also administer a battery of visual 
analogue scales (VASs) (Cowdry, 1991). For this subjective instrument to 
retain congruity with the HAMD6, we have chosen anchor points reflecting 
of the items of that instrument: No depression – Worst possible depression; 
Activities give normal pleasure – No activities give pleasure; No physical 
health concerns – Extreme health concerns; No feelings of guilt – Extreme 
feelings of guilt; Not anxious – Most anxious possible; No concentration 
problems – Most possible concentrations possible. In addition, we included a 
7th item; No sleep problems – Most sleep problems possible. These are 
constructed on a 10-cm line; totals were calculated and compared. 
Before each series, we administer the Clinical Global Impression Scale 
for Severity (CGI-S) (Guy, 1976), and on completion of each series we 
administered the CGI-Improvement (I) (Guy, 1976). These are both 7 point 
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scales; in the CGI-S, 1 indicates “normal, no illness,” while in CGI-I, 4 
indicates “no change.” 
All patients were referred by non-academic, private psychiatrists and 
were taking at least one antidepressant medication. 
We were interested in the response to a stimulation series, and the 
response to more than one series by a single individual was acceptable. 
 
Results  
 
25 series were identified (18 individuals, of whom 7 experienced 2 series). 
The average age was 53 years, and 13 (72%) were female. 
Before the series of sessions of stimulation, the average HAMD6 score 
was 7.4 – that is, the average score was in the relapse range (Table 1). Before 
the series of stimulation, HAMD6 scores indicated 22 examples of relapse. 
After the series of sessions of stimulation, the average HAMD6 score was 
3.3 – that is, the average score was in the remission range (Table 1). After 
the series of stimulation, HAMD6 scores indicated only 6 examples of relapse. 
That is, there were 16 examples of movement from relapse to remission. 
Before the series of sessions of stimulation, the average CGI-S score was 
3.4 (indicating a position between mildly and moderately ill. There was 1 
case of severe illness, 3 of markedly ill and 6 of moderate illness. There 
were no examples of “normal, no illness.” 
After the series of sessions of stimulation, the average CGI-I score was 
1.96 (indicating a position between much improved and very much improved. 
There were 5 examples of “very much improved,” 16 of “much improved” 
and none of “no change.” 
Before treatment the VASs for MDD related symptoms total was 898, 
and after this was 565, indicating a 37% improvement. 
In summary, before treatment, the HAMDS indicated relapse, and after, 
remission. Before treatment the CGI-S also indicated the presence of illness, 
and after, the CGI-I indicted considerable improvement. The VASs also 
indicated improvement. 
 
Discussion  
 
This bears the hallmarks of a non-blinded study. Bias may have played a 
hand. But, it is difficult to see how or why. Ours is a non-academic working 
facility. We have recently upgraded our outcome measures collection 
system, and staff were going about their daily activities, rather than being 
concerned about which form of treatment produced the greatest effect. 
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There may be debate that the HAMDS6 score of <5, for remission, given 
by Kyle et al. (2016), is too low. Another group argues that for the Hebrew 
version of HAMD6, the remission point should be <7 (Bachner et al., 2013). 
This needs to be seen in context, the remission point for HAMD17 is 
universally accepted as <8. To a large extent, the accepted integer is less 
important than the direction of changes. 
As a subjective measure, we chose VASs for depression related symptoms. 
These are not standardized and are of modest use in diagnosis. However, 
they are quick and simple and provide evidence of change. We used a 7-item 
battery, based on the HAMD6 questions plus one dealing with sleep problems. 
We report a 37% reduction in the pre-treatment score. This is consistent with 
our earlier VAS findings (Rybak et al., 2017) of a 47% reduction in 
depression and a 32% reduction in sleep problems.  
It is important to remember that in the pre-series assessments, the high 
HAMD6 findings are supported by the low CGI-S scores. Together, these 
indicate that many of the people in this study were in early relapse before 
they received treatment. Post-series assessments revealed a lowering of 
HAMD6 scores being substantiated by CGI-I scores indicating clear improve- 
ment. This evidence suggests that in the early stages of relapse, a short course 
of TMS is sufficient to improve the mood, possibly to the point of remission. 
For those patients with well-established MDD and history of frequent 
relapse, who respond to TMS, there is some evidence that 5 day courses of 
TMS at about monthly intervals provide benefits (Fitzgerald et al., 2013). 
This paper strongly indicates that, at least in our hands, rather than maintain 
remission, these short courses are better conceptualized as early relapse 
treatment (ERT). 
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Table 1 Pre- and Post-treatment metrics 
Client Pre-treatment 
HAMD6 Total 
Post-treatment 
HAMD6 Total 
Pre-
treatment 
VASs 
Total 
Post-
treatment 
VASs  
Total 
CGI-S CGI-I 
1 11 7 54.3 47 5 3 
2 8 2 38.3 7.4 3 1 
2 7 3 35.4 22.9 4 2 
3 4 3 32.3 15.5 2 2 
3 8 3 39.3 18.5 3 2 
4 5 2 32.8 20.6 3 2 
4 6 2 40 34.4 3 2 
4 4 2 37.9 24.1 3 3 
5 2 0 22.1 15.6 2 2 
6 7 5 25.1 29.7 3 2 
6 6 6 38.1 44.4 3 2 
7 9 2 21.2 4.5 4 2 
7 10 4 29.5 11 5 2 
8 15 7 39.1 33.4 5 2 
9 12 5 48.8 30.9 4 2 
9 8 3 53.2 24.9 3 2 
9 5 3 26.9 16 3 1 
10 5 2 45.9 12.5 3 2 
10 8 4 42.4 20.4 4 1 
11 10 6 19.8 21.8 4 2 
12 6 1 48.4 21 3 2 
13 5 1 10.7 0.7 2 3 
14 4 1 31.9 13.8 2 1 
15 5 1 42.4 33.9 3 2 
15 11 4 33 27.3 6 2 
15 6 5 28.6 34 4 3 
16 7 0 44.1 3.1 3 1 
17 5 4 37.3 31.4 3 3 
17 9 6 37.3 34.8 4 3 
18 11 8 59 46 4 3 
19 10 5 26.9 21.8 4 3 
20 5 5 27.1 25.8 3 3 
21 5 3 27.3 13.3 3 2 
       
Aver-
age 7.2 3.5 35.6 23 3.4 2.1 
 
 
 
